Design and development of a next generation product platform with a significantly greater capability also for future requirements in neuro-stimulation.
Launched development cooperation with two established companies in the field of medical device design.
Set up of two new multi-center trials in vision/optic nerve and in speech disorder (aphasia).
Second round financing is closed in December 2009 with the new lead investor Earlybird and BFB Wachstumsfond Brandenburg GmbH (Brandenburg Capital) as co-investor.
EBS Technologies is awarded a prize in the in the business plan competition Science4Life.
The first-round seed financing from the High Tech Gründerfonds and grants from the state of Brandenburg can be obtained October 2008.
Additional clinical studies with optic nerve patients in Magdeburg confirm Russian data.
The first Scientific Advisory Board is being formed.
A new prototype II is released and tested for an additional study at the Charité University of Berlin.
EBS Technologies is founded in Berlin, Germany, on November 5, 2007, with the goal of commercializing the neuro-synchronization technology and method.
Pilot clinical studies with the newly certified device, a randomized, placebo-controlled, blind study is carried out with a positive outcome: the results show that EBS can significantly enlarge the visual field in patients with optic nerve damage within 10 days, confirming the prior Russian studies.
Data collected in Russia are retrospectively and independently analyzed by Prof. Sabel (co-founder of EBS) and his team at the Institute of Medical Psychology of the Otto-v.-Guericke University of Magdeburg, Germany.
The evaluation includes the assessment of the therapy concept for the treatment of visual field defects and the verification of the know-how by an expert group.
Following approval by the ethics committee and certification of the prototype, the device is clinically used for the first time in Germany in 2007.
Dr. Anton Fedorov develops the neuro-synchronization technique in its basic form and uses a first prototype at the Human Brain Institute in St. Petersburg, Russia.
More than 1000 patients with various functional neurological are successfully treated in Russia between 1991 and 2005.
